Many scientists are targeting VEGF and its receptors to develop drugs that can inhibit the development of HCC through anti-tumor angiogenesis, such as the first-line therapeutic agent sorafenib [115]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.